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As both a user of translated measures and a scientist
interested in moving the ﬁeld forward, I am often
left after a translation project with a set of uneasy
questions about the translation process. In spite of
the care taken during the translation, have we really
found the equivalent construct in the target lan-
guage and culture? Do people who speak Spanish
and live in Mexico really understand health-related
concepts differently from those in Argentina, that is,
do we really need to go through all those compli-
cated steps of adaptation? How many people will
actually ﬁll out the scale in the language once it is
translated (almost certainly never enough to sup-
port a full psychometric validation)? If we have a
reasonably good translation such as is provided by
a forward translation and reconciliation only, how
much more value and quality are added by the back
translation and cognitive debrieﬁng steps, that is, is
the cost of performing those additional steps justi-
ﬁed? All of these examples are not abstract, but are
derived from speciﬁc experiences over the years that
have arisen in translating outcomes measures. Even
though the article by Wild et al. in this current issue
of Value in Health presenting the report of the
ISPOR Task Force on Translation and Adaptation
was at least partly aimed at laying such questions to
rest by putting out guidelines, I hope that Wild’s
article and the accompanying editorial by McKenna
and Doward (also in this issue), will actually stim-
ulate greater debate and empiric research on the
thorny problems of translation.
The ISPOR Task Force on Translation is to be
commended for their efforts to summarize the cur-
rent state of scientiﬁc knowledge on the subject of
translation. Indeed, most of us who work in the
area of outcomes research have by now had some
experience or familiarity with the translation proc-
ess. The guidelines do identify a series of steps that
are usually recommended by those who perform
translations. Unfortunately, the current recommen-
dations, while weighted by the ballast of practical
experience, lack the unfurled topsail gained by
empiric support that would allow them to sail with
full conﬁdence into a set of clear, prescriptive rec-
ommendations. For example, the recommendation
to perform a backward translation and cognitive
debrieﬁng should be supported by empirical studies
that can illustrate the consequences for reliability
and validity if such steps are not taken. Of course,
this is not the fault of the members of the Task
Force, who are merely reporting on the state of the
ﬁeld; rather, it is that it has not been heretofore
practical or urgent to conduct such methodology
work on the quality of the translation process.
We should not substitute mere established prac-
tice for empirical results that validate our methods.
It would be wonderful to see a randomized study
comparing outcomes measured using a scale trans-
lated “the quick and dirty way” (forward transla-
tion and reconciliation only) versus one translated
using the “Cadillac” approach (including all the
steps recommended by the Task Force). Then the
ﬁeld could have more conﬁdence in the recommen-
dations put forth. But who would fund such a
study? The companies who make their livelihoods
by recommending the most stringent translation
processes might understandably not wish to open
up such a can of worms. And the consumers of the
translations (often pharmaceutical companies) do
not always have the luxury of such methods studies,
because they need to focus their efforts primarily on
understanding the actual outcomes measured and
their implications for their products. Multisite stud-
ies often do not collect sufﬁcient data in each lan-
guage to truly evaluate the statistical properties of
each language version. Finally, suppose a study were
done of the type I propose above that showed there
was a meaningful difference in the reliability and
validity of two translations done using different
methodologies. How conﬁdent would we be that
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those differences could actually be generalized to
the translation process rather some ﬂaw in the
translation speciﬁc only to that language version?
So for a variety of reasons, the Task Force was left
to make their recommendations based largely on
established practice rather than empiric results. The
resulting article is generally well-written, and the
tables that illustrate the advantages and possible
pitfalls of not following a particular step in the
translation process will be useful to researchers in
the ﬁeld. Nevertheless, both the history of the Task
Force’s process and the description of the personnel
involved in the translation process made me impa-
tient, particularly because the latter read more like a
budget justiﬁcation in a proposal than a scientiﬁc
set of deﬁnitions.
In addition, I felt the conclusions and recommen-
dations were not stated clearly enough—I had to
read the article twice to be sure of what the authors
were recommending. The authors recommend that
all of the steps they list should be followed to have
a linguistically valid translation, with some allow-
ance for different approaches in accomplishing each
of these steps. The ﬂexible approach to how their
recommendations should be carried out seems prac-
tical (after all, there is more than one way to skin a
cat). But what if some of the steps must be omitted
because of time or resource constraints? What hap-
pens if one uses a measure that has only been trans-
lated using forward translation and reconciliation
versus all of the additional steps that are recom-
mended here? And, as McKenna and Doward point
out, there are alternative approaches to translation
that  the  Task  Force  has  not  described  that  may
have equal or greater utility. What about those
approaches? If researchers do not perform all of the
steps listed in the guidelines, will the resulting trans-
lation be considered invalid by regulatory bodies or
the scientiﬁc community?
In conclusion, the publication of these guidelines
and the accompanying comments by McKenna and
Doward actually reveal the need for more empirical
research on appropriate translation methodologies.
The use of item response theory approaches has a
great deal of promise for evaluating the compara-
bility of translations; randomized comparisons of
different approaches to translation would also be
very useful in helping the ﬁeld to progress forward.
These publications make one cognizant of the cur-
rent limitations of the ﬁeld. I hope the Task Force
and others will continue to provide updates to these
guidelines as more empirical research is done to
compare translation processes.
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